GE HealthCare Expands Access to Flyrcado™ Through New Distribution and Services Agreement with CDL Nuclear Technologies’ CardioNavix
GE HealthCare has announced a significant step forward in its mission to expand patient access to advanced diagnostic solutions. The company revealed that it has entered into a Distribution and Services Agreement (DSA) with CardioNavix, part of the CDL Nuclear Technologies services group. CardioNavix specializes in providing comprehensive, end-to-end cardiac positron emission tomography (PET) imaging solutions to hospitals and outpatient practices across the United States.
This new partnership is designed to strengthen the availability and reach of Flyrcado™ (flurpiridaz F18) injection, GE HealthCare’s innovative cardiac PET imaging agent. Flyrcado, approved for myocardial perfusion imaging (MPI), will now be more accessible to a broader range of patients nationwide, spanning from hospital imaging departments to private cardiology practices and outpatient facilities. The agreement supports GE HealthCare’s overarching strategy to make cardiac PET more widely available for the evaluation of known or suspected coronary artery disease (CAD)—one of the leading causes of death worldwide.
Addressing a Growing Need in Cardiac Imaging
Each year in the United States, approximately six million myocardial perfusion imaging (MPI) procedures are performed to evaluate blood flow to the heart muscle and detect CAD. While single-photon emission computed tomography (SPECT) has historically dominated the field, PET MPI has begun gaining momentum as a more precise and efficient modality. Currently, PET MPI accounts for just five to ten percent of total MPI procedures, but adoption is steadily increasing as cardiology practices and imaging providers recognize its diagnostic advantages.
The collaboration between GE HealthCare and CardioNavix is expected to accelerate this trend. Flyrcado demonstrated superior diagnostic efficacy compared to SPECT MPI in the multi-center, international Phase III AURORA clinical trial, highlighting its potential as a next-generation standard of care in cardiac imaging. By strengthening delivery channels and distribution capabilities, GE HealthCare hopes to broaden adoption of Flyrcado and enable physicians to better detect and evaluate CAD.
Leadership Perspectives
Eric Ruedinger, Vice President and General Manager of GE HealthCare’s Pharmaceutical Diagnostics division for the U.S. and Canada, emphasized the importance of this collaboration:
“This collaboration with CardioNavix is an important step in making Flyrcado available for patients nationwide, across all sites of care. CDL Nuclear Technologies is a trusted name in private cardiology and nuclear imaging, and today’s announcement underscores the confidence both organizations have in Flyrcado’s potential. This agreement helps establish the foundation needed to support GE HealthCare’s vision for Flyrcado’s growth in outpatient cardiac PET imaging and reinforces our commitment to innovation and patient-centered care.”
Echoing this sentiment, Lon Wilson, CEO of CDL Nuclear Technologies, highlighted how the agreement aligns with his company’s mission to expand access to advanced diagnostic tools:
“We’re proud that CardioNavix will be the first distributor to bring Flyrcado to private practice cardiology. Through our nearly 225 customer sites, CDL and CardioNavix support around 220,000 patient procedures each year with end-to-end cardiac PET solutions—and that number continues to grow. Together with GE HealthCare, we’re helping more providers bring advanced cardiac PET to patients in both private office-based settings and hospitals.”
Rollout Strategy and Future Expansion
The DSA represents more than just a supply agreement—it lays the groundwork for a long-term expansion strategy. GE HealthCare plans an initial roll-out of Flyrcado distribution through CardioNavix in late 2025, with wider implementation and expansion continuing into 2026 and beyond. By strategically aligning with CDL Nuclear Technologies’ established network and infrastructure, GE HealthCare aims to quickly scale adoption of Flyrcado in outpatient care, where demand for cardiac PET is steadily increasing.
GE HealthCare’s Pharmaceutical Diagnostics Division
The distribution partnership also underscores GE HealthCare’s leadership in the field of imaging agents. The company’s Pharmaceutical Diagnostics division is one of the largest global suppliers of imaging agents, supporting approximately 130 million procedures annually worldwide—the equivalent of about four procedures every second.
Its Molecular Imaging portfolio spans cardiology, neurology, and oncology, combining proven products with an ambitious pipeline of innovations. Flyrcado represents one of its most significant recent developments, promising to improve diagnostic accuracy and clinical decision-making in cardiovascular medicine. By equipping providers with advanced tools like Flyrcado, GE HealthCare seeks to drive earlier detection of disease, more personalized treatment strategies, and ultimately, better outcomes for patients.
